The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Consideration of potential drug interactions and whether discussions have occurred with a primary care provider
By enhancing glucose-dependent insulin secretion, these medications help lower blood glucose levels particularly after meals, whilst the suppression of inappropriate glucagon release prevents excessive hepatic glucose production
enrolled 3731 patients without T2DM (BMI 27 kg/m 2 or 30 kg/m 2 ) and gave LIR 3mg daily subcutaneous injection
Either option works
This finding suggests a mechanism by which these drugs might reduce drinking: if alcohol feels less rewarding, motivation to consume it decreases
